<DOC>
	<DOCNO>NCT02855957</DOCNO>
	<brief_summary>Our project aim assess validate innovative prognostic diagnostic test order ) define severity index β-thalassemia accord free α-Hb pool well management patient ; ii ) differentiate α-thalassemia β-thalassemia iii ) follow evolution pool response treatment patient . In future , prognostic test base measurement free α-Hb pool may suitable routine laboratory practice . To carry project , cohort 85 thalassemic patient group 50 healthy volunteer recruit .</brief_summary>
	<brief_title>Evaluation Free α-hemoglobin Pool Red Blood Cells : Prognostic Marker Severity Index Thalassemic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<criteria>Inclusion Criteria Patient Age ≥ 18 year Written inform consent Affiliation social security Known Hb Phenotypes Biological phenotype correspond classical picture thalassemia Healthy volunteer Age ≥ 18 year Written inform consent Affiliation social security Exclusion Criteria Patient Transfusion le 3 month Chronic active viral disease : hepatitis B , C , HIV Ongoing infection know inflammatory disease Hyper Hypothyroidism know subject treat Levothyrox Active pathology tumor remission le 5 year Oral corticosteroid Hemoglobinopathy thalassemia patient Treatment Hydroxyurea 3 month Treatment stimulate agent erythropoiesis longer 3 month Healthy volunteer Transfusion le 3 month Chronic active viral disease : hepatitis B , C , HIV Ongoing infection know inflammatory disease Hyper Hypothyroidism know subject treat Levothyrox Active pathology tumor remission le 5 year Oral corticosteroid Genetically related person hemoglobinopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Alpha-Hemoglobin Stabilizing Protein</keyword>
	<keyword>alpha-Hb pool</keyword>
	<keyword>thalassemia</keyword>
	<keyword>diagnostic method</keyword>
	<keyword>biomarker</keyword>
</DOC>